Company Performance Metrics
- Andrew Page: CTO
- Daniel Wise: CSO
Origin Sciences Limited is a UK-based biotechnology and diagnostics company developing genomic in vitro diagnostic (IVD) tests based on rectal mucus biospecimens. The company has created a proprietary sampling device (OriCol™) to collect rectal mucus, enabling analysis of biological material originating from across the gastrointestinal tract. Using
a hologenomic approach that integrates methylation, mutation, and microbial signals, Origin generates comprehensive molecular profiles for disease detection and monitoring. The test is rapid (under two minutes), requires no patient preparation, and can be performed by a trained healthcare professional.
Origin’s lead application is the detection of colorectal cancer (CRC) and high-grade dysplasia, alongside identification of advanced adenomas and other actionable gastrointestinal pathology. The platform is also being developed for additional indications including inflammatory bowel disease and pancreatic cancer.